SUMMARY. Platelet derived growth factor (PDGF) has been implicated in the pathogenesis of atherosclerosis. POGF is released by aggregating platelets and monocytes which gather around sites of arterial injury. In the study reported here the concentration of plasma POGF was measured in post myocardial infarction (MI) patients (n = 28), angina patients (n = 25), and control subjects (n = 27). Venous blood samples were taken and the concentration of PDGF determined by an enzyme linked immunosorbent assay (ELISA). Plasma PDGF concentrations were significantly higher in the post MI group compared to both the control and angina groups (P:::;;0·05). The increase in POGF concentration may be due to increased activation of platelets or monocytes since these two cells are major sources of plasma PDGF. High concentrations of POGF in the circulation could further accelerate the progression of the disease.
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An early feature in the development of atherosclerosis is believed to be endothelial cell dysfunction or injury. This is quickly followed by the attachment of leucocytes to the arterial wall and their subsequent movement into the intima where they release a cocktail of growth factors and chemokines. The major serum mitogen for smooth muscle cells is platelet derived growth factor (POGF). POGF is released by aggregating platelets at the site of endothelial injury and has been reported to stimulate the proliferation of vascular smooth muscle cells I and the chemotaxis of leucocytes.? POGF is also produced by cultured endothelial cells,' macrophages" and smooth muscle cells." This growth factor may be produced by cells within the arterial wall acting in an autocrine or paracrine manner. Under normal conditions, not only is the expression of this potent mediator of cell growth regulated, but also the regulation of the POGF receptor is stringently controlled.
Studies suggest that independent risk factors for coronary heart disease eCHO), such as Correspondence: Dr W S Gilmore. 236 diabetes and hypercholestcrolacmia, influence POGF concentrations and also POGF receptor numbers. Culture of human monocyte derived macrophages and smooth muscle cells with high concentrations of glucose results in enhanced expression of POGF-b receptor," while PDGF expression by circulating monocytes is 15-20fold higher in hypercholesterolaernic patients than in normal controls." PDGF can up regulate the low-density lipoprotein (LOL) scavenger receptor in vitro, thereby enhancing LDL uptake by macrophage foam cells. Oxidized LDL strongly enhances the production of PDGF and its receptor in human vascular smooth muscle cells."
The aim of this study was to determine, using a sensitive enzyme linked immunosorbent assay, whether plasma POGF concentration is altered in patients with vascular disease compared to apparently healthy controls.
METHODS

Subject selection
The study was approved by the Research Ethical Committee of the University of Ulster. The subjects were all men aged from 40-70 years both smokers and non-smokers. There were two patient groups: (I) those who had stable vascular disease with a history of angina but with no recent acute event (n = 25); and (2) those who had suffered a recent acute myocardial infarction (n = 28) and were subsequently attending an outpatient clinic approximately seven weeks post event. A third group (n = 28) consisted of apparently healthy volunteers, who were not being treated and showed no obvious signs of cardiovascular, cerebrovascular or peripheral vascular disease, served as a control group. Cases and control subjects suffering from other inflammatory disorders such as arthritis or asthma were also excluded from the study. All donors gave written consent and the design of and background to the study was explained to each of them at the time of donation. The subjects were required to give a 30 mL blood sample and answer a short lifestyle questionnaire. In addition the attending physician completed a short questionnaire on the patient's medical history and prescribed medication.
Sample collection
Venous blood samples were taken from each individual into pre-chilled blood collection tubes (Sherwood Medical, Ballymoney, UK) as follows: I x 10mL sample into lithium heparin anticoagulant tubes; I x 3 mL sample into an ethylenediaminetetra-acetic acid (EDTA) anticoagulant tube; all samples were held at 4"C until separated. Plasma was separated from the heparinized sample within two hours of collection to minimize any effects of storage. All plasma samples were stored at -TC until the end of the study when they were analysed together. EDTA sample was analysed using an automated haematology analyser (CELL-DYN 3500, Abbott, Maidenhead, UK).
PDCF determination
Plasma concentration of PDGF was measured using a Quantikine human PDGF-AB immunoassay (R&D Systems, Minneapolis, MN, USA). This assay employs a quantitative 'sandwich', enzyme immunoassay technique using a microtitre plate coated with PDGF-AA antibody [along with a secondary antibody for PDGF-BB]. This method therefore measures PDGF-AB. The detection limit of the assay is 84 ng/L and the interassay co-efficient of variation was 6%.
Statistics
The results are expressed as mean (sem) The effect of disease on various blood measurements was determined using ANDVA with a correction procedure for multiple comparisons (LSD). P values~0·05 were regarded as significant. Because of the skewed distribution PDGF results were transformed (square root) before analysis. In Figure I , however, the actual concentrations are displayed. All statistics were carried out using the SPSS for Windows package.
RESULTS
The mean (sem) age of the subjects was as follows: control subjects 53·7 (2'01) years; angina patients 59·2 (1'55) years; post MI patients 58-4 (1'66) years. The mean body mass index (BMI) of the subjects was as follows: angina and control groups showing significantly lower MCHC levels than the post MI group (data not shown). There was no significant difference in platelet counts between the three groups. Figure I shows the distribution of plasma platelet derived growth factor (PDGF) concentration in the three groups. The concentrations were significantly higher in the post Ml patients compared to both the control subjects and the angina patients. There was no significant difference in PDGF concentration between the control and angina groups. MI = Myocardial infarction; ACE~angiotensin-converting enzyme.
control subjects 26·27 (0·85); angina patients 25·80 (0·68); post MI patients 27·00 (0· 70). There were no significant differences between the three groups in either age or BM!. Blood samples were taken from the post-myocardial infarction (M I) patients 52 (sd 14) days after the acute event. Table I shows the various types of medication thought to influence platelet and endothelial function and the frequency of their consumption within the three groups. The total and differential white cell count is depicted in Table 2 . There was no significant difference among the three groups with respect to total white cell count, monocyte, lymphocyte and polymorphonuclear neutrophil count. There was a significant difference in the basophil count between the three groups (P';;;O·OOI), with the count significantly higher in the angina group than in post MI group. There was also a significant difference in mean cell haemoglobin concentration (MCHC) (P';;;O·OI) with both the 
DISCUSSION
Previous studies on the role of cytokines and growth factors have reported alterations in growth factor expression in patients suffering from vascular disease. However, results are as yet inconclusive and many additional studies will be required to elucidate fully the role of growth factors in the pathogenesis of atherosclerosis. In this study we have observed alterations in PDGF concentration of patients being treated for clinical symptoms of vascular disease. There were no significant differences between the three groups in age or 8MI, both of which are recognized risk factors for CHD.
Plasma PDGF concentration was significantly higher in the post MI group compared to the control subjects. Plasma PDGF concentration is dependent on the balance between production and consumption of PDGF. Factors such as thrombin, transforming growth factor-beta (TG F-fJ) and phorbol esters have been shown to increase PDGF production by endothelial cells." The increased concentration of PDGF in the post-MI patients may be due to platelet activation with increased PDGF production to repair damage caused by the ischaemic event. Once endothelial repair is complete, and the endothelium is intact, the uptake of PDGF by arterial cells would decline. Previous studies of PDGF concentrations in post MI patients have yielded conflicting results. PDGF mRNA expression is elevated in human atherosclerotic plaques compared to normal arteries." Tahara reported that plasma PDGF concentrations were correlated with the number and severity of stenosis. Comparisons between studies investigating circulating concentrations of PDGF are difficult, however, owing to the variation in time interval between MI and sample collection. We observed no significant difference in PDGF concentrations in the angina group compared to the control subjects. Again, studies examining plasma PDGF concentrations in patients with angina are inconclusive both an increase and a decrease have been reported previously.I'<" The reason for this variation is unclear. The parallel effects of dietary fish oil supplementation on PDGF mRNA expression in mononuclear cells!" and on plasma concentrations of the PDGF protein 15 suggest that mRNA levels reflect PDGF production and therefore render studies comparable. However, it should of course be remembered that unlike mRNA expression analysis, plasma growth factor concentrations reflect not only the production of cytokines but also the consumption of the factor by repairing tissue or by abnormal cell proliferation, as occurs in atherosclerosis. CHD risk factors, such as diabetes and hypercholesterolaemia, may influence production and uptake of growth factors, thereby influencing plasma growth factor concentration.v'
The source of the increased plasma PDG F concentration observed in the post-MI group is as yet unclear. Plasma PDGF, unlike serum PDGF which is mostly derived from platelets, 16 may originate from platelets, endothelial cells or monocytes. We did not observe higher platelet counts in the post MI patients. Neither did we observe any differences in monocyte count although an elevated total white cell count in both male and female post MI patients has previously been observed.!? The importance of the significantly higher basophil count recorded in the angina patients compared to the post MI group is at present unclear. Currently, the role of basophils is poorly understood although it is known that they produce heparin, a potent anticoagulant. Another source of PDGF within atherosclerotic tissue is the endothelial cell. However, endothelial cells produce predominantly PDGF-B chain mRNA I 8 and the ELISA method employed in this study does not measure PDGF-BB.
Several drugs used in the treatment of vascular disease are known to have an effect on platelet activity and endothelial function. Anti-platelet drugs such as aspirin and dipridamole reduce platelet aggregation but their effect on PDGF is contradictory and inconclusive. In vivo dipridamole significantly reduces serum PDGF concentration while aspirin has no significant effect.'? Endothelial cells and smooth muscle cells show no alteration in PDGF-A chain mRNA levels following supplementation of the culture medium with either aspirin or dipridamole.P Angiotensin-converting enzyme (ACE)-inhibitors are also known to have a modulatory effect on endothelial function, indirectly stimulating the production of nitric oxide and improving vasodilation. It has also been suggested that ACE-inhibitors can shift the balance of ongoing mechanisms in favour of those promoting vasodilatory, antiaggregatory, anti-thrombotic, and anti-proliferative effects," and, therefore, may have an effect on platelet function. Despite their widespread therapeutic use the mode of action of organic nitrates remains incompletely understood. In addition to their vasodilatory effects, this group of drugs influences platelet behaviour reducing aggregation and degranulation'? and may consequently alter PDGF release from platelets. The influence of fJ-adrenoreceptors on platelet function may also have implications for the progression of cardiovascular disease. Propranolol, a non-selective beta-adrenergic blocker, has previously been reported to reduce adenosine diphosphate and adrenaline threshold values for ex vivo platelet aggregation in hypertensive subjects, indicating an increase in platelet reactivity.P In the study reported here PDGF concentration was not associated with any of these drugs. However, in vivo these drugs are usually administered in combination, and their wide ranging effects and possible interactions render it impossible to observe the effect of a single drug on platelet/endothelial function and consequently on PDGF concentration.
The results reported here support previous studies demonstrating the involvement ofPDGF in the pathophysiology of coronary heart disease. The higher PDGF concentrations in post-MI patients observed during the course of this study, if maintained could further accelerate the progression of the disease. Further studies, including prospective studies, measuring not only the concentration of PDGF but also its activity are required to elucidate fully the role of this cytokine in vascular disease and determine the diagnostic significance of plasma PDGF concentration.
